{
    "organizations": [],
    "uuid": "be154928eb991dc4058a5cf48d2b399a66955100",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-theraclion-accelerates-its-sales-a/brief-theraclion-accelerates-its-sales-and-clinical-development-in-asia-idUSFWN1RO0SZ",
    "ord_in_thread": 0,
    "title": "BRIEF-Theraclion Accelerates Its Sales And Clinical Development In Asia",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 11 (Reuters) - THERACLION SA:\n* THERACLION ACCELERATES ITS SALES AND CLINICAL DEVELOPMENT IN ASIA\n* ECHOTHERAPY IS NOW PROPOSED IN ROUTINE CLINICAL TREATMENT IN 4 SITES IN HONG KONG AND ONE IN SINGAPORE\n* APPROVAL BY THE TAIWAN HEALTH AUTHORITIES OF ECHOPULSE IN THE TREATMENT OF BREAST FIBROADENOMA\n* ECHOPULSE: FURTHER AUTHORIZATION EVALUATIONS ARE IN PROCESS IN SOUTH KOREA AND TAIWAN (THYROID) Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-12T00:28:00.000+03:00",
    "crawled": "2018-04-12T14:12:26.014+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "theraclion",
        "sa",
        "theraclion",
        "accelerates",
        "sale",
        "clinical",
        "development",
        "asia",
        "echotherapy",
        "proposed",
        "routine",
        "clinical",
        "treatment",
        "site",
        "hong",
        "kong",
        "one",
        "singapore",
        "approval",
        "taiwan",
        "health",
        "authority",
        "echopulse",
        "treatment",
        "breast",
        "fibroadenoma",
        "echopulse",
        "authorization",
        "evaluation",
        "process",
        "south",
        "korea",
        "taiwan",
        "thyroid",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}